Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Il-Yang Pharm. Co., Ltd. clinical trials
The registry lists 34 studies whose lead sponsor is Il-Yang Pharm. Co., Ltd.. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 13, 2026.
Keep track of what changes. Save the Il-Yang Pharm. Co., Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Il-Yang Pharm. Co., Ltd..
- Il-Yang Pharm. Co., Ltd.34 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 34 of 34.
- Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic HyperplasiaNot yet recruitingNCT07870759Phase 3
- A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIsRecruitingNCT03459534Phase 3
- Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy VolunteersRecruitingNCT07433556Phase 1
- Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic UlcerRecruitingNCT06284876Phase 3
- Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)Active, not recruitingNCT03722420Phase 3
- Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CMLActive, not recruitingNCT06665412
- Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's DiseaseActive, not recruitingNCT04691661Phase 2
- Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy InfantsCompletedNCT04381689Phase 3
- Study to Evaluate the Drug-drug Interaction Between IY001 and IY002 in Healthy Adult Male Subjects.CompletedNCT07322991Phase 1
- Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics and Safety of Orally Administered RadotinibCompletedNCT06461078Phase 1
- Study to Evaluate Pharmacokinetic and Pharmacodynamic Drug Interactions and Safety of IY-NS250 and IY-NT-SRCompletedNCT06725992Phase 1
- Study to Evaluate Pharmacokinetic and Pharmacodynamic Drug Interactions and Safety of IY-HCR21 and IY-MICActive, not recruitingNCT06471868Phase 1
- Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-TCompletedNCT05509543Phase 1
- Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'CompletedNCT02677493Phase 3
- Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Ilaprazole and AceclofenacCompletedNCT05558150Phase 1
- Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Naproxen, Aceclofenac, Celecoxib and IlaprazoleCompletedNCT05237297Phase 1
- Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-TStatus unknownNCT05617651Phase 1
- Phase III Study to Evaluate Safety and Efficacy of Ilaprazole in Patients With NERDCompletedNCT03444883Phase 3
- Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean AdultsCompletedNCT02480998Phase 1/2
- Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.CompletedNCT02638584Phase 4
- Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea ChildrenCompletedNCT02263131Phase 3
- Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and AdolescentsCompletedNCT03445468Phase 3
- Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKICompletedNCT01602952Phase 1/2
- A Study on Eradication Rate of Triple Therapy According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori PatientsStatus unknownNCT03099876
- Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Clarithromycin, Amoxicillin and IlaprazoleCompletedNCT02998437Phase 1
- Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase PatientsCompletedNCT01511289Phase 3
- Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori InfectionCompletedNCT02401477Phase 4
- Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.PyloriCompletedNCT02352701
- Phase 1 Study to Assess the Safety of Inactivated Split Influenza Vaccine and Control Vaccine in Korean VolunteerCompletedNCT02330003Phase 1
- Efficacy/Safety Study as H. Pylori Eradication of Triple Therapy for 7 Days TreatmentCompletedNCT02084420Phase 3
- Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea AdultsCompletedNCT02154308Phase 3
- Immunogenicity and Safety Study of Inactivated Split Influenza Vaccine' in Healthy Korean Male SubjectsCompletedNCT02111070Phase 1
- Study to Evaluate the Pharmacokinetics, Pharmacodynamics and SafetyCompletedNCT01820143Phase 1
- Efficacy Study of Ilaprazole to Treat Erosive EsophgitisCompletedNCT01509261Phase 3